Fezolinetant Could Reduce Nighttime Awakenings in Women
A study shows the medication helps menopausal women get better rest by reducing hot flashes and sleep interruptions.
Updated on Oct. 22, 2026 in Women’s Health
Live Poll
Do you believe new non-hormonal medical treatments are effectively improving quality of life for menopausal women?
A Phase 4 study suggests that the medication fezolinetant may improve sleep quality and reduce nighttime awakenings for menopausal women. The findings, which demonstrate relief from moderate to severe hot flashes, offer a potential path forward for women struggling with menopause-related sleep disturbances.
Why it matters
Sleep disruptions affect 40% to 60% of menopausal women, with those experiencing hot flashes facing significantly higher rates of nighttime awakenings. Addressing this link is vital, as effective symptom management can improve overall quality of life during the menopausal transition.
The Phase 4 OPTION-VMS study, which utilized both patient-reported outcomes and objective wearable actigraphy, found significant improvements in sleep and vasomotor symptoms by week 12. Investigators identified no new safety concerns, with only mild and infrequent changes in hepatic laboratory findings.
The details
Fezolinetant is a selective neurokinin 3 receptor antagonist that works by blocking neurokinin B binding on neurons within the hypothalamus. By modulating this pathway, the medication helps regulate the brain's temperature control center to reduce the frequency and severity of vasomotor symptoms. This study measured success by combining subjective reports from participants with objective data captured by wearable sleep-tracking devices.
Timeline
Improvements were observed as early as week 4.
Sleep measures showed additional progress at week 8.
The study reached its primary endpoint by week 12.
Results were presented at the 2026 World Congress on Menopause.
Health Landscape
The OPTION-VMS study results were shared at the World Congress on Menopause, marking a new step in addressing the high prevalence of sleep disturbances in menopausal populations. This research contributes to a growing clinical effort to move beyond systemic treatments for vasomotor symptoms by targeting specific neurological pathways.
If you are experiencing frequent nighttime awakenings linked to hot flashes, it is worth discussing your symptoms and potential treatment options with your physician. They can help evaluate whether neurokinin 3 receptor antagonists or other therapies align with your specific health needs and history.
The takeaway
Menopause-related hot flashes can triple the rate of nighttime awakenings, making sleep a key factor to monitor. Keep a log of your sleep quality and symptom frequency to share with your healthcare provider during your next checkup.
Further reading
For more information on managing the menopausal transition, visit our Women’s Health section.
Live Poll
Do you believe new non-hormonal medical treatments are effectively improving quality of life for menopausal women?
